Normocalcemic primary hyperparathyroidism: 99mTc SestaMibi SPECT/CT results compare with hypercalcemic hyperparathyroidism
Context Normocalcemic primary hyperparathyroidism (nPHPT) is defined by an inappropriately increased serum PTH with normal serum calcium. Information about the diagnostic yield of parathyroid SPECT/CT scan and ultrasonography in nHPPT is limited and not conclusive. Purpose To evaluate the positivity...
Saved in:
| Published in | Clinical endocrinology (Oxford) Vol. 96; no. 6; pp. 831 - 836 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Wiley Subscription Services, Inc
01.06.2022
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0300-0664 1365-2265 1365-2265 |
| DOI | 10.1111/cen.14667 |
Cover
| Abstract | Context
Normocalcemic primary hyperparathyroidism (nPHPT) is defined by an inappropriately increased serum PTH with normal serum calcium. Information about the diagnostic yield of parathyroid SPECT/CT scan and ultrasonography in nHPPT is limited and not conclusive.
Purpose
To evaluate the positivity rate of 99mTc‐Sestamibi SPECT/CT scan in nPHTP compared with classical hypercalcemic PHPT (cPHPT).
Materials and Methods
We retrospectively studied 125 patients with 99mTc‐Sestamibi SPECT/CT scans. Subjects were divided into 2 groups: cPHPT (n = 93) and nPHPT (n = 32).
Results
The detection rate of 99mTc‐Sestamibi SPECT/CT in cPHPT was 86,02% (80/93) and 59.37%, in nPHPT (19/32), p = .003. No significant differences were seen between the SPECT/CT scan and ultrasonography (p = .28) and the agreement was higher in cPHPT than in nPHPT, p = .03. Sensitivity of 99m Tc‐Sestamibi‐SPECT/CT was 98% on a per‐patient basis (PPV 96%) and 91% on a per‐lesion basis (PPV 88%). Glandular size was smaller in nPHPT (mean value 6.8 mm) and it was related only with PTH value.
Conclusion
Localization rate of parathyroid hyperfunctioning tissue with 99mTc‐Sestamibi SPECT/CT is lower in nPHPT and it is related to a smaller glandular size. However, our study suggests that the positivity rate and sensitivity are nonnegligible by adding SPECT/CT. The reduction in the detection rate in nPHPT could benefit techniques with higher resolution such as 18F‐Choline PET/CT when the clinical context justifies it. |
|---|---|
| AbstractList | ContextNormocalcemic primary hyperparathyroidism (nPHPT) is defined by an inappropriately increased serum PTH with normal serum calcium. Information about the diagnostic yield of parathyroid SPECT/CT scan and ultrasonography in nHPPT is limited and not conclusive.PurposeTo evaluate the positivity rate of 99mTc‐Sestamibi SPECT/CT scan in nPHTP compared with classical hypercalcemic PHPT (cPHPT).Materials and MethodsWe retrospectively studied 125 patients with 99mTc‐Sestamibi SPECT/CT scans. Subjects were divided into 2 groups: cPHPT (n = 93) and nPHPT (n = 32).ResultsThe detection rate of 99mTc‐Sestamibi SPECT/CT in cPHPT was 86,02% (80/93) and 59.37%, in nPHPT (19/32), p = .003. No significant differences were seen between the SPECT/CT scan and ultrasonography (p = .28) and the agreement was higher in cPHPT than in nPHPT, p = .03. Sensitivity of 99m Tc‐Sestamibi‐SPECT/CT was 98% on a per‐patient basis (PPV 96%) and 91% on a per‐lesion basis (PPV 88%). Glandular size was smaller in nPHPT (mean value 6.8 mm) and it was related only with PTH value.ConclusionLocalization rate of parathyroid hyperfunctioning tissue with 99mTc‐Sestamibi SPECT/CT is lower in nPHPT and it is related to a smaller glandular size. However, our study suggests that the positivity rate and sensitivity are nonnegligible by adding SPECT/CT. The reduction in the detection rate in nPHPT could benefit techniques with higher resolution such as 18F‐Choline PET/CT when the clinical context justifies it. Normocalcemic primary hyperparathyroidism (nPHPT) is defined by an inappropriately increased serum PTH with normal serum calcium. Information about the diagnostic yield of parathyroid SPECT/CT scan and ultrasonography in nHPPT is limited and not conclusive.CONTEXTNormocalcemic primary hyperparathyroidism (nPHPT) is defined by an inappropriately increased serum PTH with normal serum calcium. Information about the diagnostic yield of parathyroid SPECT/CT scan and ultrasonography in nHPPT is limited and not conclusive.To evaluate the positivity rate of 99m Tc-Sestamibi SPECT/CT scan in nPHTP compared with classical hypercalcemic PHPT (cPHPT).PURPOSETo evaluate the positivity rate of 99m Tc-Sestamibi SPECT/CT scan in nPHTP compared with classical hypercalcemic PHPT (cPHPT).We retrospectively studied 125 patients with 99m Tc-Sestamibi SPECT/CT scans. Subjects were divided into 2 groups: cPHPT (n = 93) and nPHPT (n = 32).MATERIALS AND METHODSWe retrospectively studied 125 patients with 99m Tc-Sestamibi SPECT/CT scans. Subjects were divided into 2 groups: cPHPT (n = 93) and nPHPT (n = 32).The detection rate of 99m Tc-Sestamibi SPECT/CT in cPHPT was 86,02% (80/93) and 59.37%, in nPHPT (19/32), p = .003. No significant differences were seen between the SPECT/CT scan and ultrasonography (p = .28) and the agreement was higher in cPHPT than in nPHPT, p = .03. Sensitivity of 99m Tc-Sestamibi-SPECT/CT was 98% on a per-patient basis (PPV 96%) and 91% on a per-lesion basis (PPV 88%). Glandular size was smaller in nPHPT (mean value 6.8 mm) and it was related only with PTH value.RESULTSThe detection rate of 99m Tc-Sestamibi SPECT/CT in cPHPT was 86,02% (80/93) and 59.37%, in nPHPT (19/32), p = .003. No significant differences were seen between the SPECT/CT scan and ultrasonography (p = .28) and the agreement was higher in cPHPT than in nPHPT, p = .03. Sensitivity of 99m Tc-Sestamibi-SPECT/CT was 98% on a per-patient basis (PPV 96%) and 91% on a per-lesion basis (PPV 88%). Glandular size was smaller in nPHPT (mean value 6.8 mm) and it was related only with PTH value.Localization rate of parathyroid hyperfunctioning tissue with 99m Tc-Sestamibi SPECT/CT is lower in nPHPT and it is related to a smaller glandular size. However, our study suggests that the positivity rate and sensitivity are nonnegligible by adding SPECT/CT. The reduction in the detection rate in nPHPT could benefit techniques with higher resolution such as 18 F-Choline PET/CT when the clinical context justifies it.CONCLUSIONLocalization rate of parathyroid hyperfunctioning tissue with 99m Tc-Sestamibi SPECT/CT is lower in nPHPT and it is related to a smaller glandular size. However, our study suggests that the positivity rate and sensitivity are nonnegligible by adding SPECT/CT. The reduction in the detection rate in nPHPT could benefit techniques with higher resolution such as 18 F-Choline PET/CT when the clinical context justifies it. Normocalcemic primary hyperparathyroidism (nPHPT) is defined by an inappropriately increased serum PTH with normal serum calcium. Information about the diagnostic yield of parathyroid SPECT/CT scan and ultrasonography in nHPPT is limited and not conclusive. To evaluate the positivity rate of Tc-Sestamibi SPECT/CT scan in nPHTP compared with classical hypercalcemic PHPT (cPHPT). We retrospectively studied 125 patients with Tc-Sestamibi SPECT/CT scans. Subjects were divided into 2 groups: cPHPT (n = 93) and nPHPT (n = 32). The detection rate of Tc-Sestamibi SPECT/CT in cPHPT was 86,02% (80/93) and 59.37%, in nPHPT (19/32), p = .003. No significant differences were seen between the SPECT/CT scan and ultrasonography (p = .28) and the agreement was higher in cPHPT than in nPHPT, p = .03. Sensitivity of Tc-Sestamibi-SPECT/CT was 98% on a per-patient basis (PPV 96%) and 91% on a per-lesion basis (PPV 88%). Glandular size was smaller in nPHPT (mean value 6.8 mm) and it was related only with PTH value. Localization rate of parathyroid hyperfunctioning tissue with Tc-Sestamibi SPECT/CT is lower in nPHPT and it is related to a smaller glandular size. However, our study suggests that the positivity rate and sensitivity are nonnegligible by adding SPECT/CT. The reduction in the detection rate in nPHPT could benefit techniques with higher resolution such as F-Choline PET/CT when the clinical context justifies it. Context Normocalcemic primary hyperparathyroidism (nPHPT) is defined by an inappropriately increased serum PTH with normal serum calcium. Information about the diagnostic yield of parathyroid SPECT/CT scan and ultrasonography in nHPPT is limited and not conclusive. Purpose To evaluate the positivity rate of 99mTc‐Sestamibi SPECT/CT scan in nPHTP compared with classical hypercalcemic PHPT (cPHPT). Materials and Methods We retrospectively studied 125 patients with 99mTc‐Sestamibi SPECT/CT scans. Subjects were divided into 2 groups: cPHPT (n = 93) and nPHPT (n = 32). Results The detection rate of 99mTc‐Sestamibi SPECT/CT in cPHPT was 86,02% (80/93) and 59.37%, in nPHPT (19/32), p = .003. No significant differences were seen between the SPECT/CT scan and ultrasonography (p = .28) and the agreement was higher in cPHPT than in nPHPT, p = .03. Sensitivity of 99m Tc‐Sestamibi‐SPECT/CT was 98% on a per‐patient basis (PPV 96%) and 91% on a per‐lesion basis (PPV 88%). Glandular size was smaller in nPHPT (mean value 6.8 mm) and it was related only with PTH value. Conclusion Localization rate of parathyroid hyperfunctioning tissue with 99mTc‐Sestamibi SPECT/CT is lower in nPHPT and it is related to a smaller glandular size. However, our study suggests that the positivity rate and sensitivity are nonnegligible by adding SPECT/CT. The reduction in the detection rate in nPHPT could benefit techniques with higher resolution such as 18F‐Choline PET/CT when the clinical context justifies it. |
| Author | Musumeci, Martina San Miguel, Lucas Pereira, Lucía Valeria Vazquez, Eliana Cecilia Galich, Ana María Hume, Isabel Collaud, Carlos Cianciarelli, Constanza Arma, Irene Josefa Mollerach, Ana María |
| Author_xml | – sequence: 1 givenname: Martina orcidid: 0000-0002-9840-7225 surname: Musumeci fullname: Musumeci, Martina email: martina.musumeci@hospitalitaliano.org.ar organization: Hospital Italiano de Buenos Aires – sequence: 2 givenname: Lucía Valeria surname: Pereira fullname: Pereira, Lucía Valeria organization: Hospital Italiano de Buenos Aires – sequence: 3 givenname: Lucas surname: San Miguel fullname: San Miguel, Lucas organization: Hospital Italiano de Buenos Aires – sequence: 4 givenname: Constanza surname: Cianciarelli fullname: Cianciarelli, Constanza organization: Hospital Italiano de Buenos Aires – sequence: 5 givenname: Eliana Cecilia surname: Vazquez fullname: Vazquez, Eliana Cecilia organization: Hospital Italiano de Buenos Aires – sequence: 6 givenname: Ana María surname: Mollerach fullname: Mollerach, Ana María organization: Hospital Italiano de Buenos Aires – sequence: 7 givenname: Irene Josefa surname: Arma fullname: Arma, Irene Josefa organization: Hospital Italiano de Buenos Aires – sequence: 8 givenname: Isabel surname: Hume fullname: Hume, Isabel organization: Hospital Italiano de Buenos Aires – sequence: 9 givenname: Ana María surname: Galich fullname: Galich, Ana María organization: Hospital Italiano de Buenos Aires – sequence: 10 givenname: Carlos surname: Collaud fullname: Collaud, Carlos organization: Hospital Italiano de Buenos Aires |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34951035$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kVtLwzAYhoMobh4u_ANS8EYvuiXNqfVOyjyAJ9i8DkmasUjbzKRF5q83uunF0NyEwPM-fHm_A7DbutYAcILgCMUz1qYdIcIY3wFDhBlNs4zRXTCEGMIUMkYG4CCEVwghzSHfBwNMCoogpkPw8eh847SstWmsTpbeNtKvksVqafxSetktVt7ZyobmMimKZqaTqQmdfLDKJtPnSTkbl7PEm9DXXUi0a2LGJO-2W6wVv-I_hEdgby7rYI439yF4uZ7Mytv0_unmrry6TzWmmKc400byghdM0UorjopMKUwUqaiJL6lJ_HI-hxCTqqI5zbhiLMdUKa45YQgfgvO1d-ndWx-nF40N2tS1bI3rg8gYIhlGsZOInm2hr673bZwuUtGNipyRSJ1uqF41phKb0sRPqxEYrwHtXQjezIW2neysazsvbS0QFF97E3Fv4ntvMXGxlfiR_sVu7O-2Nqv_QVFOHteJT5Tep3Y |
| CitedBy_id | crossref_primary_10_20945_2359_3997000000556 crossref_primary_10_1210_jendso_bvad013 crossref_primary_10_1210_clinem_dgae659 crossref_primary_10_3390_medicina60010015 crossref_primary_10_1007_s12020_022_03280_9 crossref_primary_10_3390_jcm12030812 |
| Cites_doi | 10.1157/13109149 10.1001/jamasurg.2016.2310 10.1007/s40618-018-0931-z 10.1089/thy.2010.0035 10.1210/jc.2014-1414 10.1159/000491036 10.1245/s10434-011-1870-5 10.1210/jc.2002-021404 10.1210/jc.2008-1763 10.1016/j.beem.2018.09.009 10.1016/j.amjsurg.2019.10.032 10.1001/jamaoto.2019.0574 10.1007/s00198-016-3716-2 10.1038/nrendo.2017.104 10.1002/lary.26201 10.1007/s00268-012-1438-y 10.1007/s00423-019-01782-1 10.1210/jc.2007-1215 10.1007/s00268-018-4512-2 10.4158/EP15704.OR 10.1210/jc.2014-1417 |
| ContentType | Journal Article |
| Copyright | 2021 John Wiley & Sons Ltd. 2022 John Wiley & Sons Ltd. |
| Copyright_xml | – notice: 2021 John Wiley & Sons Ltd. – notice: 2022 John Wiley & Sons Ltd. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QP K9. NAPCQ 7X8 |
| DOI | 10.1111/cen.14667 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Calcium & Calcified Tissue Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Calcium & Calcified Tissue Abstracts MEDLINE - Academic |
| DatabaseTitleList | ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1365-2265 |
| EndPage | 836 |
| ExternalDocumentID | 34951035 10_1111_cen_14667 CEN14667 |
| Genre | article Journal Article |
| GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 08P 0R~ 10A 1OB 1OC 29B 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 6J9 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAKAS AAMNL AANHP AANLZ AAONW AAQQT AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABJNI ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFO ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZCM ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFNX AFFPM AFGKR AFPWT AFWVQ AFZJQ AHBTC AHEFC AHMBA AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 DUUFO EBS EJD EMOBN ESX EX3 F00 F01 F04 F5P FEDTE FUBAC FZ0 G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M J5H K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MJL MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 R.K REN RIWAO RJQFR ROL RX1 SAMSI SUPJJ TEORI UB1 V8K W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WUP WVDHM WXI WXSBR X7M XG1 YOC YUY ZGI ZXP ZZTAW ~IA ~WT AAMMB AAYXX AEFGJ AEYWJ AGHNM AGQPQ AGXDD AGYGG AIDQK AIDYY AIQQE CITATION CGR CUY CVF ECM EIF NPM 7QP K9. NAPCQ 7X8 |
| ID | FETCH-LOGICAL-c3537-32cea79796b5dcb7192bb34b4d5eb71ac41368f0034dd58527b66835bb7c74613 |
| IEDL.DBID | DR2 |
| ISSN | 0300-0664 1365-2265 |
| IngestDate | Tue Aug 05 11:35:26 EDT 2025 Mon Oct 06 18:15:20 EDT 2025 Wed Feb 19 02:26:23 EST 2025 Thu Apr 24 23:06:02 EDT 2025 Wed Oct 01 02:17:19 EDT 2025 Wed Jan 22 16:24:59 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | hypercalcemic hyperparathyroidism normocalcemic hyperparathyroidism SPECT/CT parathyroid scintigraphy |
| Language | English |
| License | 2021 John Wiley & Sons Ltd. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3537-32cea79796b5dcb7192bb34b4d5eb71ac41368f0034dd58527b66835bb7c74613 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-9840-7225 |
| PMID | 34951035 |
| PQID | 2658519864 |
| PQPubID | 36523 |
| PageCount | 6 |
| ParticipantIDs | proquest_miscellaneous_2614231349 proquest_journals_2658519864 pubmed_primary_34951035 crossref_citationtrail_10_1111_cen_14667 crossref_primary_10_1111_cen_14667 wiley_primary_10_1111_cen_14667_CEN14667 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | June 2022 2022-06-00 2022-Jun 20220601 |
| PublicationDateYYYYMMDD | 2022-06-01 |
| PublicationDate_xml | – month: 06 year: 2022 text: June 2022 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: Oxford |
| PublicationTitle | Clinical endocrinology (Oxford) |
| PublicationTitleAlternate | Clin Endocrinol (Oxf) |
| PublicationYear | 2022 |
| Publisher | Wiley Subscription Services, Inc |
| Publisher_xml | – name: Wiley Subscription Services, Inc |
| References | 2019; 8 2018; 6 2017; 6 2010; 10 2017; 1 2012; 2 2019; 4 2018; 2 2019; 51 2016; 3 2020; 1 2009; 94 2016; 10 2008; 9 2020; 105 2012; 6 2018; 11 2018; 42 2003; 10 2014; 10 2007; 26 e_1_2_8_17_1 e_1_2_8_18_1 e_1_2_8_19_1 Pierreux J (e_1_2_8_13_1) 2018; 11 e_1_2_8_24_1 e_1_2_8_14_1 e_1_2_8_15_1 e_1_2_8_16_1 e_1_2_8_3_1 e_1_2_8_2_1 e_1_2_8_5_1 e_1_2_8_7_1 Schini M (e_1_2_8_4_1) 2020; 105 e_1_2_8_6_1 e_1_2_8_9_1 e_1_2_8_8_1 e_1_2_8_20_1 e_1_2_8_10_1 e_1_2_8_21_1 e_1_2_8_11_1 e_1_2_8_22_1 e_1_2_8_12_1 e_1_2_8_23_1 |
| References_xml | – volume: 6 start-page: 761 year: 2012 end-page: 766 article-title: Surgical management of normocalcemic primary hyperparathyroidism publication-title: World J Surg – volume: 10 start-page: 3570 year: 2014 end-page: 3579 article-title: Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the fourth international workshop publication-title: J Clin Endocrinol Metab – volume: 1 start-page: 150 year: 2020 end-page: 153 article-title: Comparative prospective study on the presentation of normocalcemic primary hyperparathyroidism. Is it more aggressive than the hypercalcemic form? publication-title: Am J Surg – volume: 10 start-page: 4641 year: 2003 end-page: 4648 article-title: Normocalcemic primary hyperparathyroidism: evidence for a generalized target‐tissue resistance to parathyroid hormone publication-title: J Clin Endocrinol Metab – volume: 26 start-page: 310 year: 2007 end-page: 328 article-title: Gammagrafía de paratiroides y cirugía radiodirigida en el hiperparatiroidismo primario publication-title: Rev Esp Med Nucl Imagen Mol – volume: 10 start-page: 1121 year: 2010 end-page: 1127 article-title: Clinical appraisal of 99m technetium‐sestamibi SPECT/CT compared to conventional SPECT in patients with primary hyperparathyroidism and concomitant nodular goiter publication-title: Thyroid – volume: 2 start-page: 115 year: 2018 end-page: 125 article-title: Primary hyperparathyroidism publication-title: Nat Rev Endocrinol – volume: 51 start-page: 23 year: 2019 end-page: 39 article-title: Normocalcemic hyperparathyroidism publication-title: Front Horm Res – volume: 2 start-page: 577 year: 2012 end-page: 583 article-title: A meta‐analysis of preoperative localization techniques for patients with primary hyperparathyroidism publication-title: Ann Surg Oncol – volume: 3 start-page: 294 year: 2016 end-page: 301 article-title: Primary hyperparathyroidism, with a focus on management of the normocalcemic form: to treat or not to treat? publication-title: Endocr Pract – volume: 1 start-page: 1 year: 2017 end-page: 19 article-title: Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus publication-title: Osteoporos Int – volume: 10 start-page: 959 year: 2016 end-page: 968 article-title: The American Association of endocrine surgeons guidelines for definitive management of primary hyperparathyroidism publication-title: JAMA Surg – volume: 4 start-page: 419 year: 2019 end-page: 426 article-title: PETC/CT with 18F‐Choline localizes hyperfunctioning parathyroid adenomas equally well in normocalcemic hyperparathyroidism as in overt hyperparathyroidism publication-title: J Endocrinol Invest – volume: 94 start-page: 335 year: 2009 end-page: 339 article-title: Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop publication-title: J Clin Endocrinol Metab – volume: 42 start-page: 992 year: 2018 end-page: 997 article-title: Classic primary hyperparathyroidism versus normocalcemic and normohormonal variants: do they really differ? publication-title: World J Surg – volume: 8 start-page: 743 year: 2019 end-page: 750 article-title: Usefulness of 18F‐fluorocholine positron emission tomography‐computed tomography in locating lesions in Hyperparathyroidism: a systematic review publication-title: JAMA Otolaryngol Head Neck Surg – volume: 11 start-page: 797 year: 2018 end-page: 802 article-title: Normocalcemic primary hyperparathyroidism: a comparison with the hypercalcemic form in a tertiary referral population publication-title: Horm Metab Res – volume: 9 start-page: 3462 year: 2008 end-page: 3470 article-title: The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years publication-title: J Clin Endocrinol Metab – volume: 6 start-page: 837 year: 2018 end-page: 845 article-title: Management of normocalcemic primary hyperparathyroidism publication-title: Best Prac Res Clin Endocrinol Metab – volume: 4 start-page: 431 year: 2019 end-page: 438 article-title: Mild sporadic primary hyperparathyroidism: high rate of multiglandular disease is associated with lower surgical cure rate publication-title: Langenbecks Arch Surg – volume: 6 start-page: 1476 year: 2017 end-page: 1482 article-title: Four‐dimensional computed tomography scan utility in parathyroidectomy for primary hyperparathyroidism with low baseline intact parathyroid hormone publication-title: Laryngoscope – volume: 105 year: 2020 article-title: Normocalcemic hyperparathyroidism: study of its prevalence and natural history publication-title: J Clin Endocrinol Metab – volume: 10 start-page: 3607 year: 2014 end-page: 3618 article-title: Medical management of primary hyperparathyroidism: proceedings of the fourth International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism publication-title: J Clin Endocrinol Metab – ident: e_1_2_8_15_1 doi: 10.1157/13109149 – ident: e_1_2_8_18_1 doi: 10.1001/jamasurg.2016.2310 – ident: e_1_2_8_21_1 doi: 10.1007/s40618-018-0931-z – volume: 105 year: 2020 ident: e_1_2_8_4_1 article-title: Normocalcemic hyperparathyroidism: study of its prevalence and natural history publication-title: J Clin Endocrinol Metab – ident: e_1_2_8_16_1 doi: 10.1089/thy.2010.0035 – ident: e_1_2_8_3_1 doi: 10.1210/jc.2014-1414 – ident: e_1_2_8_5_1 doi: 10.1159/000491036 – volume: 11 start-page: 797 year: 2018 ident: e_1_2_8_13_1 article-title: Normocalcemic primary hyperparathyroidism: a comparison with the hypercalcemic form in a tertiary referral population publication-title: Horm Metab Res – ident: e_1_2_8_7_1 doi: 10.1245/s10434-011-1870-5 – ident: e_1_2_8_12_1 doi: 10.1210/jc.2002-021404 – ident: e_1_2_8_2_1 doi: 10.1210/jc.2008-1763 – ident: e_1_2_8_8_1 doi: 10.1016/j.beem.2018.09.009 – ident: e_1_2_8_10_1 doi: 10.1016/j.amjsurg.2019.10.032 – ident: e_1_2_8_19_1 doi: 10.1001/jamaoto.2019.0574 – ident: e_1_2_8_6_1 doi: 10.1007/s00198-016-3716-2 – ident: e_1_2_8_22_1 doi: 10.1038/nrendo.2017.104 – ident: e_1_2_8_20_1 doi: 10.1002/lary.26201 – ident: e_1_2_8_14_1 doi: 10.1007/s00268-012-1438-y – ident: e_1_2_8_17_1 doi: 10.1007/s00423-019-01782-1 – ident: e_1_2_8_23_1 doi: 10.1210/jc.2007-1215 – ident: e_1_2_8_11_1 doi: 10.1007/s00268-018-4512-2 – ident: e_1_2_8_9_1 doi: 10.4158/EP15704.OR – ident: e_1_2_8_24_1 doi: 10.1210/jc.2014-1417 |
| SSID | ssj0005807 |
| Score | 2.408819 |
| Snippet | Context
Normocalcemic primary hyperparathyroidism (nPHPT) is defined by an inappropriately increased serum PTH with normal serum calcium. Information about the... Normocalcemic primary hyperparathyroidism (nPHPT) is defined by an inappropriately increased serum PTH with normal serum calcium. Information about the... ContextNormocalcemic primary hyperparathyroidism (nPHPT) is defined by an inappropriately increased serum PTH with normal serum calcium. Information about the... |
| SourceID | proquest pubmed crossref wiley |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 831 |
| SubjectTerms | Calcium (blood) Computed tomography Humans Hypercalcemia hypercalcemic hyperparathyroidism Hyperparathyroidism Hyperparathyroidism, Primary - diagnostic imaging Localization Medical imaging normocalcemic hyperparathyroidism Parathyroid Parathyroid Glands - diagnostic imaging Parathyroid hormone parathyroid scintigraphy Patients Positron Emission Tomography Computed Tomography - methods Retrospective Studies Single photon emission computed tomography SPECT/CT Technetium Tc 99m Sestamibi Tomography, Emission-Computed, Single-Photon Ultrasonic imaging |
| Title | Normocalcemic primary hyperparathyroidism: 99mTc SestaMibi SPECT/CT results compare with hypercalcemic hyperparathyroidism |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fcen.14667 https://www.ncbi.nlm.nih.gov/pubmed/34951035 https://www.proquest.com/docview/2658519864 https://www.proquest.com/docview/2614231349 |
| Volume | 96 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library - Core collection (SURFmarket) issn: 0300-0664 databaseCode: DR2 dateStart: 19970101 customDbUrl: isFulltext: true eissn: 1365-2265 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0005807 providerName: Wiley-Blackwell |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8QwEB7Eg3jx_VhfRPHgpeq2adLqSZZdRNhFdAUPQmnSLC5qV_Zx0F_vTJrWN4i3PqZJm2Qy3yQzXwH2eU_GfqS5h_1rPG5S7hGLt4fWBW_IIIuMjfLtiPMbfnEb3k7BaZkLU_BDVAtupBl2viYFT9Xog5Jrk5OaC8okrwfCulNX79RRoUuVDihzWgjuWIUoiqd68rMt-gYwP-NVa3Ba83BXvmoRZ_JwOBmrQ_36hcXxn9-yAHMOiLKzYuQswpTJl2Cm7bbal-G1g2iWDJ2m8Hn2XLBSsHv0W4eWL_z-ZTjoZ_3R0wmL46euZtf4VWm7r_rs-rLZ6B41ugx9-cnjeMRcpDujVd-iiKrgHwpcgZtWs9s499yPGjwdhAFOUr42qYxlLFSYaSURNSoVcMWz0OBZqtFSiqhHXDhZhv6JL5UQCP2UklpyBBSrMJ0PcrMOjAdCIaaLZFTvcf9YqhgRLU-1MkpnMQ9qcFB2WaIdizn9TOMxKb0ZbMvEtmUN9ipR10g_CW2V_Z447R0lvqDNUiKur8FudRv1jjZT0twMJiRTRyRK5I41WCvGS1ULXiSiwhBf1vb679UnjWbHHmz8XXQTZn3KwbBLQVswPR5OzDYio7HasSrwBnfwCMI |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1JT9wwFH4CKhUudGHptJSaigOXsCSOnSAuaDRoWGaESpC4oCh2PGIEZKpZDvDr-57jhKUgIW5J7Hh_ft-znz8DrPOejP1Icw_713jcZNwjFm8PtQsGyCCPjPXy7Yr2OT-6CC-mYK86C1PyQ9QLbiQZdr4mAacF6UdSrk1Bci7kNHzgAu0UgkR_HsijQndYOqCz00JwxytEfjz1r0-10X8Q8ylitSrn4BNcVoUtPU2uNydjtanvn_E4vrc2n2HeYVG2Xw6eLzBliq_wseN22xfgvouAlnSdJg969rckpmBXaLoOLWX41d1w0M_7o9tdFse3iWZnWK2s01d9dnbaaiZbzYShOT-5GY-Yc3ZntPBbJlEn_EKCi3B-0Eqabc_d1eDpIAxwnvK1yWQsY6HCXCuJwFGpgCuehwbfMo3KUkQ9osPJczRRfKmEQPSnlNSSI6ZYgpliUJhvwHggFMK6SEY7Pe5vSxUjqOWZVkbpPOZBAzaqPku1IzKn-zRu0sqgwbZMbVs24Hcd1TXSS5FWqo5PnQCPUl_Qfilx1zdgrQ5G0aP9lKwwgwnF2UEwSvyODVguB0ydC34krsIQC2u7_fXs02arax--vz3qL5htJ52T9OSwe_wD5nw6kmFXhlZgZjycmJ8IlMZq1crDPwenDOM |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB4BlRAXoAXK8mhdxKGXQDdx7ARxQcuuKJQVKovEBUWx4xUr2OxqHwf49cw4TiiUSqi3JJ74PZ7P9vgzwC7vytiPNPewfY3HTco9YvH20LpggAyyyFgv37Y4ueKn1-H1DByWZ2EKfohqwY00w47XpOBmmHX_0HJtctJzIWfhAw_jiBz6jn8_k0eF7rB0QGenheCOV4j8eKpfX1qjvyDmS8RqTU5rCW7KzBaeJnd704na04-veBz_tzTLsOiwKDsqOs9HmDH5J5g_d7vtK_DYRkBLtk6TBz0bFsQU7BanriNLGX77MBr0st64f8DiuN_R7BKLlZ73VI9dXjQbnf1Gh-F0fno_GTPn7M5o4beIoor4jQhX4arV7DROPHdXg6eDMMBxytcmlbGMhQozrSQCR6UCrngWGnxLNRpLEXWJDifLcIriSyUEoj-lpJYcMcUazOWD3KwD44FQCOsiGdW73P8hVYyglqdaGaWzmAc1-F62WaIdkTndp3GflBMarMvE1mUNdipRV0lvCW2VDZ84BR4nvqD9UuKur8G3KhhVj_ZT0twMpiRTRzBK_I41-Fx0mCoV_EhchSFm1jb7v5NPGs22fdh4v-hXmL84biW_frbPNmHBpxMZdmFoC-Ymo6nZRpw0UV-sOjwBngAMZw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Normocalcemic+primary+hyperparathyroidism%3A+99mTc+SestaMibi+SPECT%2FCT+results+compare+with+hypercalcemic+hyperparathyroidism&rft.jtitle=Clinical+endocrinology+%28Oxford%29&rft.au=Musumeci%2C+Martina&rft.au=Pereira%2C+Luc%C3%ADa+Valeria&rft.au=San+Miguel%2C+Lucas&rft.au=Cianciarelli%2C+Constanza&rft.date=2022-06-01&rft.issn=1365-2265&rft.eissn=1365-2265&rft.volume=96&rft.issue=6&rft.spage=831&rft_id=info:doi/10.1111%2Fcen.14667&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0300-0664&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0300-0664&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0300-0664&client=summon |